Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) had its price target dropped by Morgan Stanley from $40.00 to $37.00 in a report released on Thursday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s target price would indicate a potential upside of 43.91% from the stock’s previous […]
Swiss National Bank boosted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 3.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 224,000 shares of the biotechnology company’s stock after purchasing an additional 6,700 shares during […]
Mitsubishi UFJ Kokusai Asset Management Co. Ltd. cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 12.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,552 shares of the biotechnology company’s stock after selling 1,085 shares during the […]
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) and ZyVersa Therapeutics (NASDAQ:ZVSA – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends. Insider & Institutional Ownership 66.0% of Arrowhead Pharmaceuticals […]